5.05

3.27% 0.16

After Hours: 5.05

Inmune Bio Inc (INMB)

Overview News Price History Option Chain Financials Discussions Forecast

Inmune Bio Inc stock is traded at $5.05, with a volume of 67,960. It is up +3.27% in the last 24 hours and down -19.84% over the past month. INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

Previous Close:

$4.89

Open:

$4.92

24h Volume:

67,960

Relative Volume:

0.28

Market Cap:

$111.97M

Revenue:

$155.00K

Net Income/Loss:

$-30.01M

P/E Ratio:

-3.3224

EPS:

-1.52

Net Cash Flow:

$-11.98M

1W Performance:

+3.70%

1M Performance:

-19.84%

6M Performance:

-47.67%

1Y Performance:

-45.29%

1-Day Range:

$4.86

$5.05

1-Week Range:

$4.68

$5.1302

52-Week Range:

$4.45

$14.74

Inmune Bio Inc Stock (INMB) Company Profile

Name

Inmune Bio Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

(858) 964-3720

Address

225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA

Employee

Twitter

@INmuneBio

Next Earnings Date

2024-10-31

Latest SEC Filings

INMB's Discussions on Twitter

Compare INMB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INMB Inmune Bio Inc	5.05	111.97M	155.00K	-30.01M	-11.98M	-1.67
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Inmune Bio Inc Stock (INMB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-21-24	Initiated	Alliance Global Partners	Buy
Sep-27-24	Initiated	Raymond James	Outperform
Aug-22-24	Initiated	Scotiabank	Sector Outperform
Jun-01-23	Initiated	Robert W. Baird	Outperform
May-24-22	Downgrade	B. Riley Securities	Buy → Neutral
Jul-07-21	Reiterated	Maxim Group	Buy
Apr-21-21	Initiated	B. Riley Securities	Buy
Jan-22-21	Reiterated	Maxim Group	Buy
Sep-01-20	Initiated	BTIG Research	Buy
Jul-15-20	Reiterated	H.C. Wainwright	Buy

View All

Inmune Bio Inc Stock (INMB) Latest News

Nov 27, 2024

Elevai Labs, Inc. signed a license agreement to acquire a Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology from INmune Bio, Inc.. - Marketscreener.com

Nov 27, 2024

INmune Bio (NASDAQ:INMB) Trading 1.7% Higher – Should You Buy? - Defense World

Nov 27, 2024

INmune Bio (NASDAQ:INMB) Trading 1.7% HigherWhat's Next? - MarketBeat

Nov 27, 2024

Nov 20, 2024

Scotiabank Initiates Coverage of INmune Bio (INMB) with Sector Outperform Recommendation - MSN

Nov 20, 2024

Nov 19, 2024

INmune Bio stock hits 52-week low at $4.76 amid market challenges - Investing.com

Nov 19, 2024

(INMB) Trading Report - Stock Traders Daily

Nov 19, 2024

Nov 13, 2024

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease - Marketscreener.com

Nov 13, 2024

INmune Bio Hits Major Milestone: 208 Patients Enrolled in Phase 2 Alzheimer's Trial | INMB Stock News - StockTitan

Nov 13, 2024

INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Misses Estimates By $0.11 EPS - MarketBeat

Nov 03, 2024

Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way? - Simply Wall St

Nov 03, 2024

INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023) - Yahoo Finance UK

Nov 03, 2024

Nov 01, 2024